Erlotinib

A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. (NCI04)

Chemwatch helps thousands of organisations manage chemical safety. Book a free demo to see how.
Book a Demo →
As scientists who evolve with technology we treat innovation as a way of life, a life we dedicate to improvement and advancement of Safety, Health and Environment.
© Copyright 2026 Chemwatch
Chemwatch
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.